Allergan to Buy Kythera Biopharma and Chin Fat Treatment for $2.1B

Jun 17, 2015

Botox-maker Allergan has agreed to purchase California-based Kythera Biopharmaceuticals, which is preparing to launch an injection aimed at reducing under-chin fat, in a deal worth approximately $2.1 billion in cash and stock.

The acquisition will enhance Allergan’s global facial aesthetics portfolio with the addition of Kybella injection, the first and only approved non-surgical treatment for "double chins." Kybella was granted U.S. FDA approval in late April of this year.

According to Kythera CEO Keith Leonard, the target customers for Kybella are patients already visiting the doctor for injections such as Botox.

Dublin-based Allergan will pay $75 per share for Kythera.

Read the
Allergan press release

 

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments